[Asia Economy Reporter Seo So-jung] Syntekabio, an AI-based new drug development company (CEO Jeong Jong-seon), announced on the 12th that Kim Tae-soon, Chief Operating Officer and inside director, recently resigned, and Professor Cho Hye-kyung of Sungkyunkwan University College of Pharmacy was appointed as the new CEO.
Mr. Kim started as Vice President of Syntekabio in August 2015, was promoted to Chief Operating Officer, and carried out business areas such as investment attraction and external cooperation for 5 years and 11 months.
Mr. Kim owned 6.63% of Syntekabio shares but sold 500,000 shares (3.70%) on the day to secure funds for new business. Accordingly, CEO Jeong Jong-seon plans to secure additional shares by raising funds from major institutional investors to establish a stable governance structure.
In addition, Syntekabio has established future business strategies for entering the commercialization stage of its proprietary AI drug platform DeepMatcher and operating an AI supercomputing center. To facilitate technology transfer, commercialization, and domestic and international distribution of numerous candidate drugs arising from this, Cho Hye-kyung, Chief Business Officer, was appointed as Mr. Kim’s successor.
New CEO Cho graduated from Seoul National University College of Pharmacy and is an expert in new drug clinical development and business development, having worked at global pharmaceutical companies such as Roche and BMS, and served as a professor in regulatory science at Sungkyunkwan University College of Pharmacy. The company explained that she is expected to contribute to the technical sales of Syntekabio’s new drug candidates and the commercialization of candidate discovery solutions.
Syntekabio plans to have CEO Jeong, the Chief Technology Officer (CTO), oversee the discovery of new drug candidates for license-out based on the AI drug platform, while CEO Cho will handle the commercialization of the discovered new drug candidates, establishing a professional management system that separates production, commercialization, and management.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
